Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid volume, acid-base balance, nerve impulse transmission, and muscle contraction. Dextrose provides calories and can promote protein-sparing and hepatic glycogen deposition. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion: Administer at a rate of 10-20 mEq/hour, not to exceed 200 mEq in 24 hours. The specific dose depends on the patient's electrolyte needs and fluid status. Typical maintenance: 20-40 mEq of potassium per day.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal half-life of potassium is not typically defined, but distribution half-life is approximately 1-1.5 hours. Whole-body turnover is 2-4 hours, but renal impairment prolongs elimination.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted renally (90%), with approximately 10% eliminated via the gastrointestinal tract. Excretion is influenced by aldosterone, acid-base balance, and renal function.
Category C
Category A/B
Electrolyte
Electrolyte